PathologyWatch, a Salt Lake City, UT-based digital lab and pathology platform for dermatologists, raised $25M in Series B financing.
Backers included Ceros Capital Markets, Rock Creek Capital, SpringTide, Spark Growth Ventures, Blueprint Health, Blackbrook Management Group, and existing investors.
The company intends to use the funds to broaden its outreach to dermatologists and conduct further research into skincare diagnostics and AI and support operations as the business expands across the country, adding new labs in Texas, Florida, and Arizona.
Led by Dan Lambert, CEO and cofounder, PathologyWatch provides fully interfaced EMR reporting and 24/7 access to digital slides for dermatology clinics. For their clients, this means more efficient workflows and direct access to dermatopathologists across the country, with broad insurance coverage. PathologyWatch has integrated laboratory information systems, scanners, digital viewer technology, and EMRs into an end-to-end solution for dermatologists.
FinSMEs
16/11/2021